澳门威尼克斯人(VIPWnS)网站-Venetian Platform

“A Randomized, Double-Blind, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of Subcutaneously Administered RBD5044 in Healthy Subjects”, this study is ongoing in Australia. The study has completed enrolment in the single dose-escalation phase, and is currently in the multiple dose-escalation enrolment phase.

RBD5044 is a GalNAc-siRNA drug being developed for treatment of triglycerides (TGs)-type hypertriglyceridemia. RBD5044 inhibits the expression of APOC3 (Apolipoprotein C-III) to reduce the TGs level in blood by increasing the uptake of lipoprotein lipase and hepatocyte receptor-mediated residual particle and elevating the hydrolysis of triglycerides (TGs) on triglyceride-rich lipoproteins (TRLs).